DOCSLIB.ORG

Safety Data Sheet

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Safety Data Sheet SAFETY DATA SHEET Creation Date 22-Sep-2009 Revision Date 27-Dec-2020 Revision Number 2 SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1. Product identifier Product Description: Lithium citrate tribasic tetrahydrate Cat No. : 47373 Synonyms Lithium citrate tetrahydrate Molecular Formula C6 H5 Li3 O7 . 4 H2 O 1.2. Relevant identified uses of the substance or mixture and uses advised against Recommended Use Laboratory chemicals. Uses advised against No Information available 1.3. Details of the supplier of the safety data sheet Company Thermo Fisher (Kandel) GmbH . Erlenbachweg 2 76870 Kandel Germany Tel: +49 (0) 721 84007 280 Fax: +49 (0) 721 84007 300 E-mail address [email protected] www.alfa.com Product safety Tel + +049 (0) 7275 988687-0 1.4. Emergency telephone number Carechem 24: +44 (0) 1235 239 670 (Multi-language emergency number) Poison Information Center Mainz www.giftinfo.uni-mainz.de Telephone: +49(0)6131/19240 Exclusively for customers in Austria: Poison Information Center (VIZ) Emergency call 0-24 clock: +43 1 406 43 43 Office hours: Monday to Friday, 8am to 4pm, tel: +43 1 406 68 98 SECTION 2: HAZARDS IDENTIFICATION 2.1. Classification of the substance or mixture CLP Classification - Regulation (EC) No 1272/2008 Physical hazards Based on available data, the classification criteria are not met ______________________________________________________________________________________________ ALFAA47373 Page 1 / 10 SAFETY DATA SHEET Lithium citrate tribasic tetrahydrate Revision Date 27-Dec-2020 ______________________________________________________________________________________________ Health hazards Based on available data, the classification criteria are not met Environmental hazards Based on available data, the classification criteria are not met Full text of Hazard Statements: see section 16 2.2. Label elements Hazard Statements Precautionary Statements 2.3. Other hazards SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS 3.2. Mixtures Component CAS-No EC-No. Weight % CLP Classification - Regulation (EC) No 1272/2008 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, 6080-58-6 98 - trilithium salt, tetrahydrate Full text of Hazard Statements: see section 16 SECTION 4: FIRST AID MEASURES 4.1. Description of first aid measures Eye Contact Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Get medical attention. Skin Contact Wash off immediately with plenty of water for at least 15 minutes. Get medical attention. Ingestion Do NOT induce vomiting. Get medical attention. Inhalation Remove to fresh air. If breathing is difficult, give oxygen. Get medical attention. Self-Protection of the First Aider No special precautions required. 4.2. Most important symptoms and effects, both acute and delayed No information available. ______________________________________________________________________________________________ ALFAA47373 Page 2 / 10 SAFETY DATA SHEET Lithium citrate tribasic tetrahydrate Revision Date 27-Dec-2020 ______________________________________________________________________________________________ 4.3. Indication of any immediate medical attention and special treatment needed Notes to Physician Treat symptomatically. SECTION 5: FIREFIGHTING MEASURES 5.1. Extinguishing media Suitable Extinguishing Media Water spray. Carbon dioxide (CO 2). Dry chemical. Chemical foam. Extinguishing media which must not be used for safety reasons No information available. 5.2. Special hazards arising from the substance or mixture Dust can form an explosive mixture with air. Hazardous Combustion Products Carbon monoxide (CO), Carbon dioxide (CO2). 5.3. Advice for firefighters As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear. SECTION 6: ACCIDENTAL RELEASE MEASURES 6.1. Personal precautions, protective equipment and emergency procedures Ensure adequate ventilation. 6.2. Environmental precautions See Section 12 for additional Ecological Information. 6.3. Methods and material for containment and cleaning up Sweep up and shovel into suitable containers for disposal. 6.4. Reference to other sections Refer to protective measures listed in Sections 8 and 13. SECTION 7: HANDLING AND STORAGE 7.1. Precautions for safe handling Ensure adequate ventilation. Wear personal protective equipment/face protection. Avoid contact with skin, eyes or clothing. Avoid dust formation. Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid ingestion and inhalation. Hygiene Measures Handle in accordance with good industrial hygiene and safety practice. Keep away from food, drink and animal feeding stuffs. Do not eat, drink or smoke when using this product. Remove and wash contaminated clothing and gloves, including the inside, before re-use. Wash hands before breaks and after work. ______________________________________________________________________________________________ ALFAA47373 Page 3 / 10 SAFETY DATA SHEET Lithium citrate tribasic tetrahydrate Revision Date 27-Dec-2020 ______________________________________________________________________________________________ 7.2. Conditions for safe storage, including any incompatibilities Keep in a dry, cool and well-ventilated place. Keep container tightly closed. Technical Rules for Hazardous Substances (TRGS) 510 Storage Class (LGK) Storage Class/LGK 11 (Germany) 7.3. Specific end use(s) Use in laboratories SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION 8.1. Control parameters Exposure limits This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies Component Italy Germany Portugal The Netherlands Finland 1,2,3-Propanetricarb TWA: 0.2 mg/m3 (8 oxylic acid, Stunden). MAK 2-hydroxy-, trilithium inorganic compounds, salt, tetrahydrate except Lithium and strong irritant Lithium compounds such as Lithium amide, Lithium hydride, Lithium hydroxide, Lithium nitride, Lithium oxide, Lithium tetrahydro aluminate, Lithium tetrahydroborate Höhepunkt: 0.2 mg/m3 Biological limit values This product, as supplied, does not contain any hazardous materials with biological limits established by the region specific regulatory bodies Monitoring methods BS EN 14042:2003 Title Identifier: Workplace atmospheres. Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents. MDHS14/3 General methods for sampling and gravimetric analysis of respirable and inhalable dust Derived No Effect Level (DNEL) No information available Route of exposure Acute effects (local) Acute effects Chronic effects Chronic effects (systemic) (local) (systemic) Oral Dermal Inhalation ______________________________________________________________________________________________ ALFAA47373 Page 4 / 10 SAFETY DATA SHEET Lithium citrate tribasic tetrahydrate Revision Date 27-Dec-2020 ______________________________________________________________________________________________ Predicted No Effect Concentration No information available. (PNEC) 8.2. Exposure controls Engineering Measures Ensure adequate ventilation, especially in confined areas. Ensure that eyewash stations and safety showers are close to the workstation location. Personal protective equipment Eye Protection Wear safety glasses with side shields (or goggles) (European standard - EN 166) Hand Protection Protective gloves Glove material Breakthrough time Glove thickness EU standard Glove comments Nitrile rubber See manufacturers - EN 374 (minimum requirement) Neoprene recommendations Natural rubber PVC Skin and body protection Wear appropriate protective gloves and clothing to prevent skin exposure Inspect gloves before use. observe the instructions regarding permeability and breakthrough time which are provided by the supplier of the gloves. (Refer to manufacturer/supplier for information) gloves are suitable for the task: Chemical compatability, Dexterity, Operational conditions, User susceptibility, e.g. sensitisation effects, also take into consideration the specific local conditions under which the product is used, such as the danger of cuts, abrasion. gloves with care avoiding skin contamination. Respiratory Protection When workers are facing concentrations above the exposure limit they must use appropriate certified respirators. Large scale/emergency use Use a NIOSH/MSHA or European Standard EN 136 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced Recommended Filter type: Particle filter Small scale/Laboratory use Maintain adequate ventilation Environmental exposure controls No information available. SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES 9.1. Information on basic physical and chemical properties Physical State Powder Solid Appearance White Odor Odorless Odor Threshold No data available Melting Point/Range 112 °C / 233.6 °F Softening Point No data available Boiling Point/Range No information available Flammability (liquid) Not applicable Solid Flammability (solid,gas) No information available Explosion Limits No data available Flash Point No information available Method - No information available Autoignition Temperature No data available Decomposition Temperature No data available ______________________________________________________________________________________________ ALFAA47373 Page 5 / 10 SAFETY DATA SHEET Lithium citrate tribasic tetrahydrate Revision Date 27-Dec-2020 ______________________________________________________________________________________________
Load more

Recommended publications
  • Report of the Advisory Group to Recommend Priorities for the IARC Monographs During 2020–2024
    IARC Monographs on the Identification of Carcinogenic Hazards to Humans Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024 Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024 CONTENTS Introduction ................................................................................................................................... 1 Acetaldehyde (CAS No. 75-07-0) ................................................................................................. 3 Acrolein (CAS No. 107-02-8) ....................................................................................................... 4 Acrylamide (CAS No. 79-06-1) .................................................................................................... 5 Acrylonitrile (CAS No. 107-13-1) ................................................................................................ 6 Aflatoxins (CAS No. 1402-68-2) .................................................................................................. 8 Air pollutants and underlying mechanisms for breast cancer ....................................................... 9 Airborne gram-negative bacterial endotoxins ............................................................................. 10 Alachlor (chloroacetanilide herbicide) (CAS No. 15972-60-8) .................................................. 10 Aluminium (CAS No. 7429-90-5) .............................................................................................. 11
    [Show full text]
  • BNSSG Shared Care Guidance Please Complete All Sections
    NHS Bristol North Bristol NHS Trust NHS North Somerset University Hospitals Bristol NHS Foundation Trust NHS South Gloucestershire Weston Area Health NHS Trust BNSSG Shared Care Guidance Please complete all sections AMBER 3 month Section 1: Heading Avon & Wiltshire Mental Health Partnership NHS Trust Trust(s) Speciality / Department Mental Health Agreement for Lithium Drug (please prescribe by brand name and specify formulation: Priadel, Camcolit®, Liskonum®, Li-Liquid® ) 1. The management of acute manic or hypomanic episodes. 2. The management of episodes of recurrent depressive disorders where treatment with other antidepressants has Indication been unsuccessful. 3. The prophylaxis against bipolar affective disorders. 4. Control of aggressive behaviour or intentional self harm. Section 2: Treatment Schedule Dosage is adjusted based on serum-lithium concentration. Lithium levels must be taken 12 hours post dose, otherwise clinical value is lost. Lithium has a narrow therapeutic range necessitating blood levels between 0.4-1.2mmol/L. The lower end of this range is used for elderly and infirmed patients and the upper end for younger patients, particularly those being treated for an episode of mania. Clinicians should aim for levels of 0.6-0.8 mmol/L, with higher levels possibly being of benefit for patients with predominantly manic symptoms. Usual dose and frequency of Rarely 1.2mmol/L may be used. administration The starting dose is usually 400mg at night (200mg in the elderly), adjusted to achieve the desired serum-lithium concentration. Bloods should be taken 12 hours post dose. For tablet preparations dose is usually given as a single dose at night; for liquid preparations, the dose may be spilt to twice a day.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak Et Al
    USOO9642912B2 (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak et al. (45) Date of Patent: *May 9, 2017 (54) TOPICAL FORMULATIONS FOR TREATING (58) Field of Classification Search SKIN CONDITIONS CPC ...................................................... A61K 31f S7 (71) Applicant: Crescita Therapeutics Inc., USPC .......................................................... 514/171 Mississauga (CA) See application file for complete search history. (72) Inventors: Edward T. Kisak, San Diego, CA (56) References Cited (US); John M. Newsam, La Jolla, CA (US); Dominic King-Smith, San Diego, U.S. PATENT DOCUMENTS CA (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Santa Barbara, 5,602,183 A 2f1997 Martin et al. CA (US); Wade A. Hull, Kaysville, UT 5,648,380 A 7, 1997 Martin 5,874.479 A 2, 1999 Martin (US); Ngoc Truc-ChiVo, Longueuil 6,328,979 B1 12/2001 Yamashita et al. (CA) 7,001,592 B1 2/2006 Traynor et al. 7,795,309 B2 9/2010 Kisak et al. (73) Assignee: Crescita Therapeutics Inc., 8,343,962 B2 1/2013 Kisak et al. Mississauga (CA) 8,513,304 B2 8, 2013 Kisak et al. 8,535,692 B2 9/2013 Pongpeerapat et al. (*) Notice: Subject to any disclaimer, the term of this 9,308,181 B2* 4/2016 Kisak ..................... A61K 47/12 patent is extended or adjusted under 35 2002fOOO6435 A1 1/2002 Samuels et al. 2002fOO64524 A1 5, 2002 Cevc U.S.C. 154(b) by 204 days. 2005, OO 14823 A1 1/2005 Soderlund et al. This patent is Subject to a terminal dis 2005.00754O7 A1 4/2005 Tamarkin et al.
    [Show full text]
  • Therapeutic Drug Monitoring Clinical Guide FOURTH EDITION
    DIAGNOSTICS Therapeutic Drug Monitoring Clinical Guide FOURTH EDITION 1 Therapeutic Drug Monitoring Clinical Guide FOURTH EDITION Authors Mike Hallworth, MA, MSc, FRCPath Former Consultant Biochemist Royal Shrewsbury Hospital United Kingdom Ian Watson, MSc, PhD, FRCPath Former Consultant Biochemist and Toxicologist University Hospital Aintree Liverpool, United Kingdom Editors of the David Holt, DSc, PhD Third Edition Susan Tett, PhD, BPharm (Hons), MPS Steven H. Wong, PhD, DABCC (TC), FACB 2 CONTENTS THERAPEUTIC DRUG MONITORING . 5 RUFINAMIDE . 81 WHY IS TDM NECESSARY? . 6 TIAGABINE . 83 WHICH DRUGS SHOULD BE MONITORED? . 8 TOPIRAMATE . 85 PRACTICAL CONSIDERATIONS . 10 VALPROATE . 87 CALCULATION OF DOSAGE ADJUSTMENT . 15 VIGABATRIN . 89 OTHER APPROACHES TO OPTIMIZING THERAPY — ZONISAMIDE . 91 PHARMACOGENETICS AND BIOMARKERS . 17 ANTIFUNGALS . 94 EFFECTIVENESS OF TDM – DOES IT HELP PATIENTS? . 19 POSOCONAZOLE/VORICONAZOLE . 95 REFERENCES . 21 ANTINEOPLASTICS . 98 WEBSITES . 23 BUSULFAN . 99 DRUG DATA PROFILES . 24 METHOTREXATE . 101 PREFACE . 24 ANTIRETROVIRALS . 104 ADDICTION THERAPEUTICS . 28 ANTIRETROVIRALS . 105 BUPRENORPHINE . 29 BRONCHODILATOR, ANALEPTIC . 108 METHADONE . 31 THEOPHYLLINE . 109 ANALGESICS . 34 CAFFEINE . 111 ACETAMINOPHEN (PARACETAMOL) . 35 CARDIAC AGENTS . 114 ACETYLSALICYLIC ACID (ASPIRIN) . 37 ANTI-ARRHYTHMICS MORPHINE . 39 AMIODARONE . 115 ANTIBIOTICS . 42 DISOPYRAMIDE . 117 AMINOGLYCOSIDES FLECAINIDE . 119 AMIKACIN . 43 LIDOCAINE . 121 GENTAMICIN . 45 CARDIAC GLYCOSIDES TOBRAMYCIN . 47 DIGOXIN . 123 OTHER ANTIBIOTICS
    [Show full text]
  • A History of the Pharmacological Treatment of Bipolar Disorder
    International Journal of Molecular Sciences Review A History of the Pharmacological Treatment of Bipolar Disorder Francisco López-Muñoz 1,2,3,4,* ID , Winston W. Shen 5, Pilar D’Ocon 6, Alejandro Romero 7 ID and Cecilio Álamo 8 1 Faculty of Health Sciences, University Camilo José Cela, C/Castillo de Alarcón 49, 28692 Villanueva de la Cañada, Madrid, Spain 2 Neuropsychopharmacology Unit, Hospital 12 de Octubre Research Institute (i+12), Avda. Córdoba, s/n, 28041 Madrid, Spain 3 Portucalense Institute of Neuropsychology and Cognitive and Behavioural Neurosciences (INPP), Portucalense University, R. Dr. António Bernardino de Almeida 541, 4200-072 Porto, Portugal 4 Thematic Network for Cooperative Health Research (RETICS), Addictive Disorders Network, Health Institute Carlos III, MICINN and FEDER, 28029 Madrid, Spain 5 Departments of Psychiatry, Wan Fang Medical Center and School of Medicine, Taipei Medical University, 111 Hsin Long Road Section 3, Taipei 116, Taiwan; [email protected] 6 Department of Pharmacology, Faculty of Pharmacy, University of Valencia, Avda. Vicente Andrés, s/n, 46100 Burjassot, Valencia, Spain; [email protected] 7 Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University, Avda. Puerta de Hierro, s/n, 28040 Madrid, Spain; [email protected] 8 Department of Biomedical Sciences (Pharmacology Area), Faculty of Medicine and Health Sciences, University of Alcalá, Crta. de Madrid-Barcelona, Km. 33,600, 28871 Alcalá de Henares, Madrid, Spain; [email protected] * Correspondence: fl[email protected] or [email protected] Received: 4 June 2018; Accepted: 13 July 2018; Published: 23 July 2018 Abstract: In this paper, the authors review the history of the pharmacological treatment of bipolar disorder, from the first nonspecific sedative agents introduced in the 19th and early 20th century, such as solanaceae alkaloids, bromides and barbiturates, to John Cade’s experiments with lithium and the beginning of the so-called “Psychopharmacological Revolution” in the 1950s.
    [Show full text]
  • Mental Health Medications
    Mental Health Medications National Institute of Mental Health U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES UÊÊ >Ì>ÊÃÌÌÕÌiÃÊvÊi>Ì Contents Mental Health Medications ..............................................................1 What are psychiatric medications? .....................................................1 How are medications used to treat mental disorders? .......................................1 What medications are used to treat schizophrenia? ............................................2 What are the side effects? ............................................................2 How are antipsychotics taken and how do people respond to them? ...........................3 How do antipsychotics interact with other medications? ....................................3 What medications are used to treat depression? ..............................................4 What are the side effects? ............................................................4 How should antidepressants be taken? ..................................................5 Are herbal medicines used to treat depression? ...........................................5 FDA warning on antidepressants.......................................................6 What medications are used to treat bipolar disorder? . .7 Mood stabilizers ...................................................................7 Atypical antipsychotics ..............................................................7 Antidepressants ....................................................................7 What are the
    [Show full text]
  • Guidance on the Use of Mood Stabilisers for the Treatment of Bipolar Affective Disorder
    Guidance on the use of mood stabilisers for the treatment of bipolar affective disorder GUIDELINE NO RATIFYING COMMITTEE DRUGS AND THERAPEUTICS GROUP DATE RATIFIED July 2013 DATE AVAILABLE ON INTRANET NEXT REVIEW DATE July 2015 POLICY AUTHORS Jules Haste, Lead Pharmacist, Brighton and Hove Members of the Pharmacy Team (contributors are listed overleaf) . If you require this document in an alternative format, ie easy read, large text, audio, Braille or a community language please contact the pharmacy team on 01243 623349 (Text Relay calls welcome). Page 1 of 52 Contributors Jed Hewitt, Chief Pharmacist - Governance & Professional Practice James Atkinson, Pharmacist Team Leader Mental Health and Community Services Miguel Gomez, Lead Pharmacist, Worthing. Hilary Garforth, Lead Pharmacist, Chichester. Pauline Daw, Lead Pharmacist (CRHTs & AOT), East Sussex. Iftekhar Khan, Lead Pharmacist (S&F Service), East Sussex. Graham Brown, Lead Pharmacist CAMHS & EIS. Gus Fernandez, Specialist Pharmacist MI and MH Lisa Stanton, Specialist Pharmacist Early Intervention Services & Learning Disabilities. Nana Tomova, Specialist Pharmacist, Crawley. Jamie Richardson, Specialist Pharmacist, Crawley. Page 2 of 52 Section Title Page Number 1. Introduction and Key Points 4 2. Flowcharts: Suggested Treatment plans (from BAP guidance) 2.1 Acute mania or mixed episode 6 2.2 Acute depressive phase 7 2.3 Long term or maintenance treatment 8 3. General principles in the treatment of acute mania or mixed 9 episode 4. General principles in the treatment of acute depressive phase 10 5. General principles in long term or maintenance treatment 12 6. Rapid cycling 14 7. Physical health 14 8. Treatment in special situations 8.1 Pregnancy 15 8.2 Breast-feeding 17 8.3 Older adults 19 8.4 Children and adolescents 22 8.5 Learning disabilities 27 8.6 Cardiac dysfunction 29 8.7 Renal dysfunction 31 8.8 Hepatic dysfunction 34 8.9 Epilepsy 38 9.
    [Show full text]
  • LITHIUM PRESCRIBING GUIDELINES Lithium for The
    Lithium prescribing guidelines LITHIUM PRESCRIBING GUIDELINES Lithium for the treatment and prophylaxis of mania, bipolar disorder and recurrent depression Version: Date: Author: Status: Comment: Document Author Written by: Francis Johnson Signed: Date: 1/10/2014 Job Title: Mental health specialist pharmacist Approval DAC: December 2014 Trust Executive Committee date: July 2015 CCG Board date: January 2015 Review Date: October 2019 Effective Date: October 2015 Version Control History: Version: Date: Author: Status: Comment: August 2014 1 Lithium prescribing guidelines These guidelines have been produced to support the seamless transfer of lithium prescribing and patient monitoring from secondary to primary care and provides an information resource to support clinicians providing care to the patient. This guideline was prepared using information available at the time of preparation, but users should always refer to the manufacturer’s current edition of the Summary of Product Characteristics (SPC or “data sheet”) for more details. August 2014 2 Lithium prescribing guidelines CONTENTS PAGE SECTION DESCRIPTION PAGE 1 INTRODUCTION 4 2 INDICATIONS 4 3 PREPARATION 4 4 SAFETY ISSUES 5 4.1 Dose 5 4.2 Contra-indications (also see current BNF or SPC) 5 4.3 Cautions 5 4.4 Common Side Effects (also see current BNF or SPC) 5 4.5 Drug Interactions (also see current BNF or SPC) 5 4.6 Pre-treatment Assessment 6 4.7 Routine Safety Monitoring 6 5 RESPONSIBILITY OF CONSULTANT 6 6 RESPONSIBILITY OF NURSE (if applicable) 6 7 RESPONSIBILITY OF GP 6 8 RESPONSIBILITY
    [Show full text]
  • Lithium Carbonate
    Capsules: 150 mg, 300 mg, 600 mg of lithium carbonate (3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ------------------------------ CONTRAINDICATIONS ----------------------------- LITHIUM and LITHIUM CARBONATE safely and effectively. See full prescribing information for LITHIUM and LITHIUM CARBONATE. Known hypersensitivity to any inactive ingredient in the drug product. (4) ----------------------- WARNINGS AND PRECAUTIONS ---------------------- LITHIUM oral solution, for oral use LITHIUM CARBONATE tablets, for oral use Lithium-Induced Polyuria: May develop during initiation of treatment. LITHIUM CARBONATE capsules, for oral use Increases risk of lithium toxicity. Educate patient to avoid dehydration. Monitor for lithium toxicity and metabolic acidosis. Discontinue lithium Initial U.S. Approval: 1970 or treat with amiloride as a therapeutic agent (5.2). Hyponatremia: Symptoms are more severe with faster-onset hyponatremia. Dehydration from protracted sweating, diarrhea, or WARNING: LITHIUM TOXICITY elevated temperatures from infection increases risk of hyponatremia and lithium toxicity. Educate patients on maintaining a normal diet with salt See full prescribing information for complete boxed warning. and staying hydrated. Monitor for and treat hyponatremia and lithium toxicity, which may necessitate a temporary reduction or cessation of Lithium toxicity is closely related to serum lithium concentrations, lithium and infusion of serum sodium (5.3). and can occur at doses close to therapeutic concentrations. Facilities Lithium-Induced Chronic Kidney Disease: Associated with structural for prompt and accurate serum lithium determinations should be changes in patients on chronic lithium therapy. Monitor kidney function available before initiating therapy (2.3, 5.1). during treatment with lithium (5.4). Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic.
    [Show full text]
  • LITHIUM CARBONATE Tablets USP LITHIUM CARBONATE Capsules USP LITHIUM Oral Solution USP
    4055500//08 Roxane Laboratories, Inc. Columbus, Ohio 43216 LITHIUM CARBONATE Tablets USP LITHIUM CARBONATE Capsules USP LITHIUM Oral Solution USP WARNING Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Fa cil i ties for prompt and accurate serum lithium de ter mi na tions should be avail able before initiating ther apy (see DOSAGE AND ADMINISTRATION). DESCRIPTION Each tablet for oral admini stra tion contains: Lithium Carbonate .......300 mg Each capsule for oral admini stra tion contains: Lithium Carbonate 150 mg, 300 mg or 600 mg Each 5 mL of solution for oral administration contains: Lithium ion (Li+) .............8 mEq (equivalent to amount of lithium in 300 mg of lithium carbonate), alcohol 0.3% v/v. Inactive Ingredients The tablets contain cal cium stearate, mi crocrys talline cellulose, povidone, so dium lauryl sulfate, and sodium starch gly- colate. The capsules contain FD&C Red No. 40, gelatin, so dium lauryl sulfate, talc, ti ta nium dioxide, and the imprinting ink contains FD&C Blue No. 2, FD&C Yellow No. 6, FD&C Red No. 40, iron oxide, polyvinyl pyrrolidone, and shellac. The solution contains citric acid, raspberry blend, sodium benzoate, sorbitol, and water. Lithium Oral Solution is a palatable oral dosage form of lithium ion. It is prepared in solution from lithium hydroxide and citric acid in a ratio approxi mately di-lithium citrate. Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer.
    [Show full text]
  • FDA Approval Status and Research Evidence Quality - Psychotropic Medications in Children
    Table: FDA Approval Status and Research Evidence Quality - Psychotropic Medications in Children II. MOOD STABILIZING ANTICONVULSANT AGENTS AND LITHIUM SECTION CONTRIBUTORS: Robert Kowatch, M.D., Boris Lorberg, M.D., Yana Turkowski, M.D., Julie Zito, Ph.D. A. LITHIUM Grade for How Labeled Psychiatric Well Indicated Generic Name Indication for Mood Medication is Comments/ Age (Yrs) Pregnancy (Trade Name) and Stabilization Studied for Pediatric Psychiatric Research for Mood Category Class (Month/Year if Pediatric References/ Other Indications Stabilization available) Mood Stabilization Lithium Carbonate 12+ a Bipolar D isorder - Manic A FDA indication for age 12+ D (Eskalith, Eskalith- episode appears to be extrapolated from CR, Lithobid), research among patients older Lithium Citrate Bipolar Disorder - than 18. Mood stabilizer/ Maintenance therapy Anti-mania/ (Findling et al, 2005, 2011, 2013) Antidepressant (Geller et al., 1998, 2012) (Kowatch, Strawn, et al., 2009) (Dickstein et al., 2009) (Kafantaris et al., 2003, 2004) In TEAM study, 2nd effective of 3 agents for pediatric Bipolar I mania or mixed mood: risperidone>lithium>valproic acid (Geller et al., 2012), (Vitiello et al., 2012). B. MOOD STABILIZING ANTICONVULSANT AGENTS Generic Name Indicated Labeled Psychiatric Grade for How Comments/ Pregnancy (Trade Name) and Age (Yrs) for Indication for Mood Well Pediatric Psychiatric Research Category Class Mood Stabilization (Month/Year Medication is References/ Other Indications Stabilization if available) Studied for Pediatric Mood Stabilization Carbamazepine 18+ Bipolar I Disorder - Acute C Off-label for pediatric Bipolar D (Carbatrol, Epitol, manic and mixed Disorder. Tegretol,Tegretol episodes (Ginsberg, 2006) XR, Equetro) (Kowatch et al., 2000) Anticonvulsant/ Anti-mania/ FDA-approved 0+ for Epilepsy.
    [Show full text]
  • Module #5. Optional Training Psychotropic Medications And
    Module #5. Optional Training Psychotropic Medications and Children and Adolescents The following training provides information on psychotropic medications, their use with children and adolescents in general and with children and adolescents in foster care in particular, and specific types of psychotropic medications. There are eight sections in this training: Section #1: What are Psychotropic Medications? Section #2: Psychotropic Medication and Children and Adolescents Section #3: Psychotropic Medications and Children in Foster Care Section #4: Psychotropic Medications and Anxiety Disorders (Including PTSD) Section #5: Psychotropic Medication and ADHD Section #6: Depression and Psychotropic Medications Section #7: Psychotropic Medication and Bipolar Disorder Module #8: Psychotropic Medication and Schizophrenia Section #9: Resources on Psychotropic Medications Here are the learning objectives for this training. At the conclusion of this training, you will be able to: #1. State why psychotropic medications are generally used. #2. Name two critical issues that must be taken into account in using psychotropic medications with children and adolescents. #3. Identify four concerns about the current usage of psychotropic medications with children and adolescents in foster care. #4. Identify three major types of psychotropic medications used to treat anxiety disorders, including PTSD. #5. Name three very common side effects of psychotropic medications used for the treatment of ADHD. #6. Describe the FDA warning regarding the use of antidepressants in the treatment of children and adolescents 1 #7. Identify two major types of psychotropic medications used in the treatment of bipolar disorder #8. Define an “atypical antipsychotic” and list two benefits of this type of drug for the treatment of schizophrenia. At the conclusion of this training, there is a test that you can take to assess your learning.
    [Show full text]